Telmisartan Shows Organoprotection and Reduces the Incidence of Adverse Cardiovascular Outcomes in Addition to the Antihypertensive Effect

HYPERTENSION

doi 10.22141/2224-1485.4.48.2016.76998

Full Text

Abstract

Available in

Date

September 19, 2016

Authors

A.V. Savustyanenko

Publisher

Publishing House Zaslavsky

Related search

Antihypertensive Medication Exposure and Cardiovascular Outcomes in Hemodialysis Patients

American Journal of Nephrology

English

Follow-Up Shows No Adverse Outcomes of CNEP in Neonates

English

The Incidence of Isolated Single Umbilical Artery in Twins and Adverse Pregnancy Outcomes

Prenatal Diagnosis

English

Living in Food Deserts and Adverse Cardiovascular Outcomes in Patients With Cardiovascular Disease

Journal of the American Heart Association

Cardiovascular Medicine

English

Incidence of Adverse Cardiovascular Events in Adults Following Drug Overdose

Academic Emergency Medicine

Emergency Medicine

English

An Improved Synthesis of Telmisartan: An Antihypertensive Drug

Organic Chemistry

English

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial†

Journal of Clinical Lipidology

Internal Medicine

Cardiovascular Medicine

English

The Effects of Angiotensinogen Gene Polymorphisms on Cardiovascular Disease Outcomes During Antihypertensive Treatment in the GenHAT Study

Frontiers in Pharmacology

English

Cardiovascular Protective Effect of Metformin and Telmisartan: Reduction of PARP1 Activity via the AMPK-PARP1 Cascade

Multidisciplinary

English